Afatinib in NSCLC With HER2 Mutation

PHASE2CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

March 18, 2016

Primary Completion Date

July 22, 2018

Study Completion Date

July 22, 2018

Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
DRUG

afatinib

DRUG

paclitaxel

Trial Locations (9)

59100

University Malaya Medical Centre, Kuala Lumpur

200032

Zhongshan Hospital Fudan University, Shanghai

200433

Shanghai Pulmonary Hospital, Shanghai

210029

First Hospital Affiliated with Nanjing Medical University, Nanjing

310022

Zhejiang Cancer Hospital, Hangzhou

330006

The Second Affiliated Hospital to Nanchang University, Nanchang

410013

Hunan Province Tumor Hospital, Changsha

450008

Henan Cancer Hospital, Zhengzhou

510120

First Affiliated Hospital of Guangzhou Medical University, Guangzhou

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY